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S U M M A R Y
Background: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has spread
throughout the world with varying regional incidences and different staphylococcal cassette
chromosome mec (SCCmec) elements in different genetic backgrounds. No information is available
on CA-MRSA in Iran. A cross-sectional study was carried out among healthy students to investigate: (1)
the prevalence of CA-MRSA in Central Iran, (2) the molecular epidemiology of such CA-MRSA strains, (3)
the antimicrobial resistance patterns of the strains, and (4) the distribution of virulence genes in these
CA-MRSA strains.
Methods: A total of 700 nasal swabs were collected and subjected to S. aureus and MRSA-speciﬁc
isolation procedures. Antimicrobial resistance patterns were determined using the disk diffusion
method, and molecular typing was carried out by multi-locus sequence typing (MLST), SCCmec typing,
and Staphylococcus protein A (spa) typing for all CA-MRSA isolates. PCR was used to detect various
virulence genes.
Results: One hundred ﬁfty-four S. aureus strains were isolated from the anterior nares of 700 healthy
students. According to the US Centers for Disease Control and Prevention deﬁnitions for CA-MRSA, seven
(4.5%) isolates were conﬁrmed as CA-MRSA. CA-MRSA isolates belonged to SCCmec types IV (n = 6) and V
(n = 1). The predominant spa-type among the CA-MRSA isolates was t790 (n = 3), with single t660, t084,
and t325 isolates; one isolate was not typeable. The predominant sequence type was ST22, t790, SCCmec
IV in three isolates, and the four other sequence types were ST25, ST859, ST14, and ST15.
Conclusions: Iranian CA-MRSA strains are genetically diverse with an elevated prevalence of t790/ST22
SCCmec IV isolates. These ﬁndings support the need for more effective infection control measures to
reduce nasal carriage and prevent dissemination of CA-MRSA in Iran.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a serious
threat to hospitalized patients globally and represents a challenge
for public health, as community-acquired (CA) infections appear to
be on the increase in both adults and children in various regions.
CA-MRSA was ﬁrst documented in children with infections in the
USA in the late 1990s.1,2
The global epidemiology of CA-MRSA is remarkably heteroge-
neous. In some regions, a single clone dominates (e.g., USA300 in
the USA), whereas in other regions, multiple clones have been* Corresponding author. Tel.: +98 8614173526.
E-mail address: e.ghaznavirad@arakmu.ac.ir (E. Ghaznavi-Rad).
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http://dx.doi.org/10.1016/j.ijid.2013.03.023identiﬁed (e.g., 100 different clones have been described in
Australia).3 Recently, virulence genes such as those encoding
Panton–Valentine leukocidin (PVL, pvl gene) and exfoliative toxin
(ET, et gene) have been associated with emerging CA-MRSA clones
and speciﬁc clinical presentations.4
CA-MRSA containing the genes encoding PVL have spread all
over the world with various incidences and characterizing
different genetic backgrounds.5 For instance, the sequence type
(ST) 8 USA300 clone has been detected relatively frequently in
North and South America and Spain, whereas the ST80 clone has
been found to be the major European CA-MRSA clone, which is also
frequently detected in Algeria.6 Multiple additional PVL-positive
CA-MRSA clones have been reported,7 but no information is
available on the epidemiology of CA-MRSA in Central Iran.8 The
aim of the current study was to evaluate the molecularses. Published by Elsevier Ltd. All rights reserved.
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carriers.
2. Methods
2.1. Bacterial isolates and MRSA detection
Seven hundred volunteers (437 females and 263 males; mean
age 22.7 years) from the Arak University of Medical Sciences
(Arak, Iran) campus, without symptoms or signs of clinical
illness, were enrolled in the study over a 3-month period.
Institutional ethical approval was obtained prior to study
commencement. The healthy volunteers had not used anti-
biotics during the past 2 months and had no history of
hospitalization, admission to a nursing home, skilled nursing
facility, or hospice, dialysis because of renal failure, or recent
surgery, and they had had no permanent indwelling catheters or
medical devices that pass through the skin at least during
the past year (which constitutes a risk factor for CA-MRSA).2 In
fact, these students were studying only in the medical faculty
and were not being exposed to the hospital environment or
patients.
Samples were collected from both anterior nares of the
volunteers by rotating a sterile Transwab with Amies clear
transport medium (MW170 Transwabs; Medical Wire and
Equipment Company, Corsham, UK). Swabs were transported to
the Department of Medical Microbiology and Immunology at Arak
University of Medical Sciences and cultured.
The isolates were presumptively identiﬁed as S. aureus by
standard biochemical tests for catalase, coagulase, clumping factor,
DNase, and thermostable nuclease. All isolates were also evaluated
for the presence of the sa442 gene by PCR.9
Methicillin resistance was detected by disk diffusion testing
with a cefoxitin 30-mg disk (Mast, UK) and an oxacillin 10 mg disk
(Mast, UK), in accordance with the guidelines issued by the Clinical
and Laboratory Standards Institute (CLSI).
Isolates were also tested by MRSA screen latex agglutination
(Denka Seiken Co., Ltd, Tokyo, Japan), and oxacillin minimum
inhibitory concentrations (MICs) were determined using the Etest
system (bioMe´rieux, Marcy l’Etoile, France). The presence of the
mecA gene was veriﬁed by PCR only for phenotypically oxacillin-
resistant isolates.Table 1
PCR primers and cycling parameters for genes presented in this study
Gene Primer/sequence PCR 
sea F: TTGGAAACGGTTAAAACGAA
R: GAACCTTCCCATCAAAAACA
1 min
seb F: TCGCATCAAACTGACAAACG
R: GCAGGTACTCTATAAGTGCC
1 min
sec F: GCATAAAAGCTAGGAATTT
R: AAATCGGATTAACATTATCC
1 min
seg F: AATTATGTGAATGCTCAACCCGATC
R: AACTTATATGGAACAAAAGGTACTAGTTC
1 min
seh F: CAATCACATCATATGCGAAAGCAG
R: CATCTACCCAAACATTAGCACC
1 min
sei F: CTCAAGGTGATATTGGTGTAGG
R: AAAAAACTTACAGGCAGTCCATCTC
1 min
eta F: CTAGTGCATTTGTTATTCAA
R: TGCATTGACACCATAGTACT
1 min
etb F: ACGGCTATATACATTCAATT
R: TCCATCGATAATATACCTAA
1 min
tsst F: ATGGCAGCATCAGCTTGATA
R: TTTCCAATAACCACCCGTTT
1 min
pvl F: ATCATTAGGTAAAATGTCTGGACATGATCCA
R: GCATCAASTGTATTGGATAGCAAAAGC
30 s 
arcA F: GAGCCAGAAGTACG
R: CACGTAACTTGCTAGAACGAG
30 s 2.2. Antimicrobial susceptibility testing
For all CA-MRSA isolates, antimicrobial resistance patterns
were determined using a panel of 17 antibiotic disks in accordance
with the Kirby–Bauer method (CLSI and The European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines,
2011). Antibiotics included gentamicin, amikacin, netilmicin,
levoﬂoxacin, co-trimoxazole, mupirocin, quinupristin–dalfopris-
tin, ciproﬂoxacin, cefoxitin, oxacillin, rifampin, linezolid, fusidic
acid, clindamycin, tetracycline, tigecycline, and erythromycin. The
MIC to vancomycin was determined by Etest (bioMe´rieux). S.
aureus ATCC 25923 was used as a control strain in the antibacterial
susceptibility testing. Intermediate sensitivity was scored as
resistance. Enterococcus faecalis ATCC 29212 and Enterococcus
faecium BM4147 were used as controls for vancomycin suscepti-
bility and vancomycin resistance, respectively.
2.3. Detection of virulence genes by PCR
A DNA extraction kit (BioFlux, Bioer, Korea) was used for
puriﬁcation of genomic DNA from all CA-MRSA strains; the
manufacturer’s instructions were followed. PCR was used for
ampliﬁcation of genes encoding PVL (pvl), arcA as an indicator of
the arginine catabolic mobile element (ACME), exfoliative toxins A
and B (eta and etb), staphylococcal enterotoxins A, B, C, G, H, and I
(sea, seb, sec, seg, seh, and sei), and toxic shock syndrome toxin
(tsst). All primers and programs can be found in Table 1.10,11
2.4. Molecular diversity of CA-MRSA based on spa typing
The short sequence repeat (SSR) X region of the spa gene was
ampliﬁed using the primers forward: 50-AGACGATCCTTCGGT-
GAGC-30, and reverse: 50-GCTTTTGCAATGTCATTTACTG-30, as
described by Shopsin et al.12 A ready-to-use PCR master mixture
(Sina Clone, Iran) was used in a ﬁnal volume of 50 ml, consisting of
10 ml of master mix, 0.1 ml of forward primer and 0.1 ml of reverse
primer, 38.8 ml of distilled water, and 1 ml of DNA template in a
0.5-ml microcentrifuge tube. PCR incubation mixtures were
subjected to a quick spin before being placed in an Eppendorf
thermocycler (Germany). PCR was carried out as described by
Harmsen et al.13 using the following cycling parameters: initial
denaturation of 10 min at 95 8C, followed by 30 cycles ofconditions PCR size Reference
 94 8C, 1 min 55 8C, 1 min 72 8C 120 bp 10
 94 8C,1 min 55 8C, 1 min 72 8C 478 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 257 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 642 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 372 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 576 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 119 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 200 bp 10
 94 8C, 1 min 55 8C, 1 min 72 8C 350 bp 10
94 8C, 30 s 55 8C, 30 s 72 8C 433 bp 11
94 8C, 30 s 55 8C, 30 s 72 8C 770 bp
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extension at 72 8C, and a ﬁnal extension at 72 8C for 10 min. S.
aureus ATCC 25923 was used as positive control, while sterile
deionized water was used as negative control. Ampliﬁed PCR
products were visualized after agarose gel electrophoresis (60
Volts, 500 mA, and duration of 60 min). Puriﬁed PCR products were
sequenced (DNA Sequencer ABI, model 3730-XL) commercially
(Gene Fanavaran, Iran) using the spa primers. The sequences
obtained were subjected to spa repeat analysis and spa typing
using the SpaServer (http://www.spaserver.ridom.de).
2.5. Multi-locus sequence typing (MLST)
For all CA-MRSA isolates, the ST was determined by MLST.
Partial gene sequences of seven housekeeping genes (arcC, aroE,
glpF, gmk, pta, tpi, and yqiL) were determined by PCR and direct
sequencing, and their allelic proﬁle (allele numbers) and ST were
obtained using the S. aureus MLST database (http://www.mlst.net)
hosted by Imperial College in London, UK.14
2.6. SCCmec typing
The structure of SCCmec was determined by the method
developed by Ghaznavi-Rad et al.15
3. Results
One hundred ﬁfty-four S. aureus strains were isolated from the
anterior nares of 700 healthy students. Overall, seven isolates (IR1
to IR7) were resistant to methicillin and were conﬁrmed as CA-
MRSA based on the detection of the mecA gene and the overall lack
of features suggesting hospital-related acquisition. The antimicro-
bial resistance patterns of these CA-MRSA isolates are shown in
Table 2.
According to the results of the vancomycin Etest, all isolates
were susceptible to this agent. The highest rates of susceptibility
were observed with amikacin (100%, n = 7), gentamicin (100%, n =
7), netilmicin (100%, n = 7), and co-trimoxazole (100%, n = 7). Six of
seven isolates (85.8%) were susceptible to ciproﬂoxacin, levoﬂox-
acin, rifampin, and mupirocin, while four of seven isolates (57.1%)
were susceptible to erythromycin, clindamycin, and tetracycline.
Five different proﬁles were identiﬁed by MLST: ST22, ST14,
ST15, ST25, and ST859. spa typing discriminated four different
types: t790, t084, t325, and t660; one strain was not spa-typeable
(Table 3). Six isolates belonged to SCCmec type IV (85.8%) and one
isolates showed SCCmec type V (14.3%).
ST22, SCCmec type IV, spa-type t790 strains (IR4, IR5, and IR6)
were determined as the predominant clone in Central Iran. The
prevalence of seb, eta, and pvl genes in CA-MRSA strains were all
14.3%, and the prevalence of sec, sei, tsst, arcA, seg, and seh genes
were 28.5%, 28.5%, 28.5%, 28.5%, 42.8%, and 42.8% respectively,
whereas the sea and etb genes were not found in our strains. TheTable 2
Antimicrobial resistance patterns of CA-MRSA isolates
MRSA isolates AK GEN NET CIP LZD FUS MUP TGC 
IR1 S S S S S S S S 
IR2 S S S R S S S R 
IR3 S S S S R R R S 
IR4 S S S S S S S S 
IR5 S S S S S S S S 
IR6 S S S S S R S S 
IR7 S S S S S R S S 
CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; R, resistant;
LZD, linezolid; FUS, fusidic acid; MUP, mupirocin; TGC, tigecycline; LEV, levoﬂoxacin; TS,
T, tetracycline; FOX, cefoxitin; OXA, oxacillin; VAN, vancomycin; RP, rifampin.frequencies of virulence factor genes in CA-MRSA isolates are
presented in Table 3.
Two of the ST22 strains were isolated from students partici-
pating in the same course. The strains also shared identical
antibiogram proﬁles but displayed different virulence gene
patterns.
4. Discussion
The present study describes the detection and molecular
characterization of CA-MRSA from healthy Iranian students
without an obvious CA-MRSA acquisition risk. Data obtained
during this study show that the S. aureus nasal carriage rate among
healthy students was 22%, which is within the reported range.16
MRSA screening revealed seven CA-MRSA isolates (7/700
subjects (1%) or 7/154 S. aureus isolates (4.5%)) colonizing normal
healthy students who had no risk factors. This is slightly higher
than the rate reported in many previous reports. Despite the global
increase in community-associated infections, rates of MRSA
carriage in the healthy population remain low in most parts of
the world. Pooled data from 10 studies (8350 patients) showed a
prevalence of 1.3% for CA-MRSA colonization. After excluding those
with MRSA acquisition risk factors, the prevalence of CA- MRSA
was only 0.2%.17
It has been reported that CA-MRSA from different parts of the
world have different genetic backgrounds.18 ST8 SCCmec type IV
(USA300 clone) is the predominant clone in North America, while
community-associated MRSA in Europe is characterized by clonal
heterogeneity; several clones seem to have emerged in Europe
such as the ST398-V pig-associated clone (which was reported
ﬁrst in The Netherlands19 and Denmark20), a PVL-positive ST152-
V clone in the Balkan region,21 ST150 clone in Sweden, PVL-
negative clones causing infections in injecting drug users in
Switzerland (ST45) and the UK (ST1),22 and an ST377-V clone in
Greece.1
Evaluation of CA-MRSA in Asian countries showed that the most
predominant clones in these regions included: ST59-MRSA-
SCCmec type IV-spa-type t437 in Taiwan, Hong Kong, Vietnam,
and Sri Lanka; ST30-MRSA-SCCmec type IV-spa-type t019 in the
Philippines; and ST72-SCCmec type IV-spa type t324 in Korea.23
By application of various typing methods, three CA-MRSA
strains (IR4, IR5, and IR6) were characterized as spa-type t790,
ST22, SCCmec type IV, being PVL-negative in this study. One of
these t790/ST22 strains (IR6) was found to contain the sec, she, and
tsst virulence genes, which is similar to a strain isolated from our
neighboring country Abu Dhabi.24 Another t790/ST22 strain (IR5)
was found to carry seg and seh enterotoxin genes; this is the ﬁrst
ST22-ACME arcA-positive strain from Iran. It is similar to the ST22-
CA-MRSA that has previously been reported from Dublin, Ireland.25
The ST22/t790 strain (IR4) was found to carry sec, sei, and seg
enterotoxin genes. The ST22 clone has previously been reported as
a predominant CA-MRSA clone in Germany.26LEV TS CLI E SYN T FOX OXA VAN RP
S S R R S S R R S S
R S R R S S R R S S
S S R R R R R R S R
S S S S S S R R S S
S S S S S S R R S S
S S S S S R R R S S
S S S S S R R R S S
 S; susceptible; AK, amikacin; GEN, gentamicin; NET, netilmicin; CIP, ciproﬂoxacin;
 co-trimoxazole; CLI, clindamycin; E, erythromycin; SYN, quinupristin–dalfopristin;
Table 3
Molecular characterization and virulence factor genes of CA-MRSA isolates
MRSA isolates spa type SCCmec ST Allelic proﬁle PVL arcA eta etb sea seb sec sei seg seh tsst
IR1 T660 IV ST25 4-1-4-1-5-5-4         +  +
IR2 Unknown V ST-14 1-13-1-1-12-11-13        +   
IR3 t084 IV ST15 13-13-1-1-12-11-13 + + +   +     
IR4 t790 IV ST22 7-6-1-5-8-8-6       + + +  
IR5 t790 IV ST22 7-6-1-5-8-8-6  +       + + 
IR6 t790 IV ST22 7-6-1-5-8-8-6       +   + +
IR7 t325 IV ST859 79-1-14-23-12-4-31          + 
CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; SCCmec, staphylococcal cassette chromosome mec; ST, sequence type; PVL, Panton–Valentine
leukocidin.
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and IR5 strains were susceptible to non-beta-lactam agents, while
the IR6 strain was resistant to tetracycline and fusidic acid.
ST22-MRSA-IV (EMRSA-15) is a pandemic CC22-MRSA strain. It
emerged in the UK in 1991. Since then, it has become one of the
dominant strains in that region and is currently considered one of
the global hospital-acquired (HA)-MRSA pandemic clones. In
Dresden, Portugal, Malta, and the Azores it accounted for 50%, 54%,
66%, and 80% of MRSA isolates, respectively.27 Nevertheless, ST22-
MRSA-IV occurs in hospitals as well as in outpatient settings.28
Recently, it was reported to be carried asymptomatically by a few
(5/879) healthy individuals without associated health care risk
factors in Ireland.29 Another study reported carriage of EMRSA-15
in people using urban Portuguese public buses.30 In addition a
single ST22-MRSA-IVa, spa t223, pvl gene-negative strain was
detected in 64% of MRSA strains isolated from the noses of healthy
children and their parents throughout the Gaza Strip.31 It should be
noted that seven strains of ST22 methicillin-susceptible S. aureus
(MSSA) were recently found as the causative agents of nosocomial
infections that occurred in Alzahra Hospital in Isfahan, Iran; no
ST22 MRSA was detected in that study.32 This ﬁnding conﬁrms the
fact that transmission of S. aureus from the community to hospitals
and vice versa could easily happen. This state could gradually cause
the loss of a clear-cut border between the two populations (CA and
HA).
The fourth CA-MRSA strain (IR7) in our study belongs to t325,
ST859, SCCmec type IV; this was found to be she-positive and only
resistant to tetracycline and fusidic acid. ST859 IV has already been
reported as PVL-negative HA-MRSA in Iran.32 The presence of this
particular strain in both the community and hospital suggests that
this strain is actively circulating in the region.33
The ﬁfth strain (IR1) belongs to ST25, SCCmec type IV, t660; this
strain was found to be tsst- and seg-positive, and resistant to
erythromycin and clindamycin. ST25 has been identiﬁed as CA-
MRSA, but only very rarely. However, MSSA of ST25 has been
encountered as a predominant clone in Algeria, the USA, France,
and Paraguay.34 In a study from China, ST25-V-t081, ST25-V-t078,
and ST25-t078 were isolated from the noses of students on a
medical campus.35
Only one out of the seven CA-MRSA (IR3 strain; t084, ST15,
SCCmec type IV) was found to be both PVL- and ACME-positive.
This strain was found to harbor eta and seb virulence genes. ST15
has been reported to represent a successful lineage among CA- and
HA-MSSA isolates and is the most disseminated clone; it has been
identiﬁed in 11 different European countries.36 Nevertheless,
Rasigade et al. found ﬁve PVL-positive ST15 strains among the 211
S. aureus isolates that were collected from 19 different countries in
a multicenter study.34 Currently PVL-positive CA-MRSA have
become a serious public health concern because of their virulence,
their ability to cause outbreaks in households and close contact
social groups, and their rapid spread in many countries.
Importantly, in our study, this strain was found to be linezolid-
and quinupristin–dalfopristin-resistant, which is the ﬁrst reportfrom Iran. In addition this strain was also resistant to erythromy-
cin, clindamycin (constitutive), rifampin, tetracycline, fusidic acid,
and mupirocin.
The last CA-MRSA strain in this study (IR2 strain) was non-
typeable by the spa method and belongs to ST14 SCCmec type V; it
was found to be only sei-positive. This strain was determined to be
multiple drug resistant (MDR) and appears to be resistant to
erythromycin, clindamycin (constitutive), ciproﬂoxacin, and levo-
ﬂoxacin. In addition this strain is the ﬁrst tigecycline-resistant
strain reported from Iran. It has been shown that ST14-t279-V
belonging to CC15 is one of the lineages that cannot provide a
stable genomic environment for the integration of SCCmec.
However, this strain has been isolated from infection sites in
patients in long-term care at a Spanish hospital.37
Although highly virulent CA-MRSA strains carrying PVL
genes are known to prevail in the world,38 in this study only
one strain (IR3) was found to carry the pvl gene and the
prevalence of PVL-positive strains was low. CA-MRSA patho-
genesis has been linked to PVL, which is produced by the
majority of CA-MRSA isolates; however, the absence of PVL is no
proof against community origin. This was documented in
Australia, Japan, and China, where the majority of CA-MRSA
isolates lack PVL.18,35,38
A previous study showed that the toxin gene seh was associated
with persistent S. aureus bacteremia.39 This would suggest that
three of the seven strains (IR5, IR6, and IR7) isolated in the present
study carrying the seh gene have a high potential to cause
bacteremia.
In this study, six of seven (85.8%) CA-MRSA strains were found
to carry SCCmec type IV and the remaining strain (14.3%) to carry
SCCmec type V. Data published from the different HA-MRSA clones
indicate that ST239-III is the predominant HA-MRSA clone
circulating in Iranian hospitals.32,40,41 According to the results of
the present study, SCCmec typing can be used as an epidemiologi-
cal marker for differentiation between CA and HA MRSA.
Mupirocin is broadly used to treat MRSA skin and soft tissue
infections and to eliminate nasal MRSA colonization among
patients and medical staff. Our study shows that 14.3% of CA-
MRSA strains were resistant to mupirocin, which is in agreement
with mupirocin resistance rates observed in another study.35
Therefore, mupirocin can be used as a decolonization agent for
reducing nasal MRSA carriage in the Iranian community.
ST8 (USA300) and ST80 (European clone) have not been found
in Central Iran. The ST8 and ST80 MRSA clones are obviously rare in
Asian countries.23 To conﬁrm that these clones are not found in
Iran, further studies should be performed in different parts of the
country.
Further studies of the molecular epidemiology of CA-MRSA
should be done in different population groups (such as sports
teams and children) and at other body sites as well.
The present study was limited by the inclusion of healthy
student volunteers. In addition, the evaluation of virulence
determinants was based on their qualitative assessment by PCR.
A. Japoni-Nejad et al. / International Journal of Infectious Diseases 17 (2013) e949–e954 e953We did not assess quantitative expression of these genes or the
presence of single nucleotide polymorphisms, which may inﬂu-
ence the function of gene products.42
Although the overall prevalence of CA-MRSA is presently low
worldwide, there is clear evidence that this is increasing in most
part of the world, such as the USA, Canada, Australia, and
Europe.17,43 HA-MRSA and CA-MRSA strains are often genotypi-
cally and phenotypically different, however it is difﬁcult to
distinguish between CA-MRSA and HA-MRSA on clinical and
epidemiological assessment. Further investigations are needed to
determine stringent criteria rather than SCCmec type, PVL gene,
and antibiotic susceptibility patterns to establish a precise
deﬁnition of CA-MRSA.
In conclusion, Iranian CA-MRSA clones are diverse, although
clonal dissemination of the ST22 type strain indicates that the
spread of ecologically successful European clones to the Asian
continent continues. The emergence of linezolid, tigecycline, and
quinupristin–dalfopristin resistance should be taken seriously.
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